Tetrastatin, a 230 amino acid sequence from collagen IV, was previously demonstrated to inhibit melanoma progression. In the present paper, we identified the minimal active sequence (QKISRCQVCVKYS: QS-13) that reproduced the anti-tumor effects of whole Tetrastatin in vivo and in vitro on melanoma cell proliferation, migration and invasion. We demonstrated that QS-13 binds to SK-MEL-28 melanoma cells through the α v β 3 integrin using blocking antibody and β3 integrin subunit siRNAs strategies. Relevant QS-13 conformations were extracted from molecular dynamics simulations and their interactions with α V β 3 integrin were analyzed by docking experiments to determine the binding areas and the QS-13 amino acids crucial for the binding. The in silico results were confirmed by in vitro experiments. Indeed, QS-13 binding to SK-MEL-28 was dependent on the presence of a disulfide-bound as shown by mass spectroscopy and the binding site on α V β 3 was located in close vicinity to the RGD binding site. QS-13 binding inhibits the FAK/ PI 3 K/Akt pathway, a transduction pathway that is largely involved in tumor cell proliferation and migration. Taken together, our results demonstrate that the QS-13 peptide binds α v β 3 integrin in a conformationdependent manner and is a potent antitumor agent that could target cancer cells through α V β 3 .
QS-13 peptide binds to SK-MEL-28 through the α v β 3 integrin. To determine whether QS-13 binds to the α v β 3 integrin on melanoma cells, we measured SK-MEL-28 cell adhesion on QS-13 peptides in the presence or absence of an anti-α v β 3 integrin blocking antibody (10 µg/mL). The blocking anti-α v β 3 antibody significantly inhibited (40%) cell adhesion on QS-13, whereas an irrelevant IgG had no effect ( Fig. 2a) .
Moreover, SK-MEL-28 extracts were analysed by QS-13 peptide affinity chromatography. Proteins bound to the affinity column were eluted with increasing concentrations of NaCl (0.15, 0.6 and 1.0 M). Eluted samples were submitted to sodium dodecyl sulfate (SDS)-poly-acrylamide gel electrophoresis (PAGE) and analysed by western blot. The 0.6 M eluted samples revealed bands that matched the recombinant α v and β 3 integrin subunits (Fig. 2b) .
To confirm that the α v β 3 integrin acts as a receptor for QS-13 on SK-MEL-28 cells, β 3 integrin expression was decreased by specific siRNA transfection. The β 3 integrin mRNA and protein levels were evaluated by RT-qPCR and western blot, respectively. β 3 integrin siRNA transfection decreased β 3 integrin mRNA expression by 91% ( Fig. 2c ) and protein expression by 65% ( Fig. 2d, supplementary Fig. S1 ). Control siRNAs did not significantly modify β 3 subunit expression. Transfected cells were seeded on the QS-13 peptide. Control siRNAs did not significantly modify cell adhesion. By contrast, β 3 subunit siRNAs decreased cell adhesion by 50% ( Fig. 2d ). Taken together, our results confirm that the α v β 3 integrin is a receptor of QS-13 on SK-MEL-28 cells.
QS-13 peptide presents a disulfide bond in solution.
MALDI-ToF MS analyses demonstrated that the QS-13 peptide (m/z 1543) ( Fig. 3a) formed an intra-chain disulfide-bond between 222 C and 225 C of Tetrastatin in solution over time (Fig. 3b ). The disulfide-bond was reduced by dithiothreïtol ( Fig. 3c ).
Molecular dynamics (MD) simulation of QS-13. The first objective of the MD simulation was to explore and characterize the intrinsic structural behaviour of the investigated peptides, specifically the role of the experimentally evidenced disulfide bond and potential key residues. The second objective was to select relevant QS-13 conformations that can be used for docking experiments on integrin α v β 3 . From the different 200 ns NPT simulations performed on a set of 10 different peptides ( Supplementary Table S1 ), clustering analyses allowed us to identify the different types of conformations that occurred along the trajectory. One striking observation was that the presence of the disulfide bond between the 222 C and 225 C was directly responsible for the occurrence of a lower number of clusters (see Supplementary Table S2 ). Indeed, for the four peptides presenting a disulfide bond, there was at least one division by two of the number of clusters compared to the peptide without the disulfide bond. In addition, the observation and superposition of the MD trajectory showed that the structure of the CQVC portion was almost frozen in the same conformation ( Fig. 4a , left panel) for these 4 peptides and that the Q and V middle residues never explored a coil conformation, favouring a bend or a turn local structure. In addition, transitioning from the disulfide bond structure to the structure without the disulfide bond, the increase in the number of clusters was accompanied by a decrease in the percentage of structures found in the five first clusters.
Comparing the structures with ( Fig. 4a , left panel) and without ( Fig. 4a , central panel) the disulfide bond, it is quite understandable that since the peptides without the disulfide bond "explore" a larger configuration space, they are characterized by a larger number of clusters. Another interesting feature is illustrated in the right panel of Fig. 4a : not only is the structure of the CQVC portion almost frozen for a given peptide, but by aligning the representative structures (i.e., the first cluster) of the four peptides containing a disulfide bond, we showed that they fit very well and that they almost conserved the same orientation and exposure of the QV and R side chains towards the outside of the bond.
When we analysed the global content of the secondary structures, the major observation was an increase of the coil structure when the disulfide bond was present. An increase of the β-bridge or β-sheet structure were found when cysteine or arginine residues were mutated into alanine residues.
The different clusters studied below are listed in Fig. 4b . Figure 4c presents the secondary structures of QS-13 first and second clusters of the QS-13 peptide that were used in the docking experiments. From these representations, we observed that the disulfide bond locked CQVC in a conformation that exposed the glutamine side chain. The side chain exposure was explored systematically for all of the MD simulations ( Supplementary Fig. S2 ). Two Scientific REPORTs | (2018) 8:9837 | DOI:10.1038/s41598-018-28003-x factors strongly modified the general profile of the solvent accessible surface (SAS) of the peptide: the loss of the disulfide bond and modification of glutamine, arginine or cysteine residues, especially, when one of the cysteine residues was mutated into alanine.
Docking experiments of QS-13 on α V β 3 . For each QS-13 peptide (listed in Fig. 4b ), we collected 27000 (180 × 150) structures from the docking experiments. To overcome the bias introduced by the forced exploration of empty or unfavourable interaction areas, we kept the first 180 lowest energy structures and studied them in detail. These structures were then spatially regrouped in clusters to allow identification of the most probable interacting surface protein areas. For each QS-13 peptide, we identified the preferred areas of interaction (PAI) with the integrin; at the most, five were identified. In the left panel of Fig. 4d , the five PAIs found with the QS-13-3 peptide (also representative of the results obtained with the other peptides) are shown. Most often for 4 QS-13 peptides out of the 6 investigated through docking, as shown in Fig. 4b , PAI-5 was the area that had the highest frequency (see Table S3 ). From the energetic point of view, the negative binding energies accounted for the favourable interactions between the QS-13 peptide and this area of α v β 3 . On average, PAI-3 was the least populated area. It was not explored by the QS-13-2 peptide, and in 3 of the 5 experiments, the lowest binding energy did not traduce any favourable interaction since it was close to zero. Other than PAI-3, which could be removed from the potential interacting areas, it seemed difficult to remove the remaining PAI. Looking at the energy, 2 out of the 6 peptides seemed to be very interesting, QS-13-5 and QS-13-6, since they had at least 4 of the lowest binding energies below the threshold of −3.00 kcal/mol. New docking experiments were performed with bonded QS-13, positioning the centres of the grid search on the centre of mass of each PAI. Following this protocol, we were able to identify the residues of the integrin that interacted directly the QS-13 peptides (central and right panel of Fig. 4d ). It was interesting to observe that among the residues that made contact with the QS-13 peptide, the aspartic acid residue was one of the most common, followed by glutamic acid, tyrosine and serine. Focusing the contact investigation on the best binding energy structure obtained in the PAI-1 region, we again highlight the fact that the contacts made by QS-13 mostly involved these four types of residues in the protein.
Finally, when we compare our docking results with 1L5G PDB structure 20 , we observe that the position of PAI-1 is colocalized with the region of interaction between the RGD peptide and the integrin.
RGDS peptide inhibits QS-13 binding to SK-MEL-28 cells. Based on the docking experiments, we
evidence that one of the five hypothetical QS-13-binding areas (PAI-1) overlaps the RGD binding site 20 . To test this hypothesis, SK-MEL-28 melanoma cells were preincubated with different concentrations of RGDS peptide (from 1 to 20 µg/mL) or with an anti-α v β 3 integrin blocking antibody (10 µg/mL) and seeded on QS-13 coated 96-well plates. As shown in Fig. 5a , cell preincubation with RGDS inhibited cell adhesion to the QS-13 peptide similarly to the anti-α v β 3 integrin blocking antibody. These results provide evidence that the QS-13 binding site may be the RGD binding site or a new site in close proximity to the RGD binding site on integrin α v β 3 and suggest that the first theoretical area (PAI-1) identified by the docking experiments may represent the real binding site.
222
C and 225 C of Tetrastatin are crucial for QS-13 binding to SK-MEL-28 cells. Molecular dynamics simulation and docking experiments highlighted the importance of several QS-13 sequences in binding to the α v β 3 integrin. Six substituted peptides labelled with biotin on their C-terminus were synthesized ( Fig. 5b ). Their binding to SK-MEL-28 cells was evaluated by flow cytometry (Fig. 5c ). The different substitutions decreased peptide binding to α v β 3 (Fig. 5d ). Substitution of 222 C and 225 C completely abolished the adhesion and by the way, cell proliferation, migration and invasion ( Supplementary Fig. S3 ). By mass spectroscopy, we showed that the QS-13 peptide forms an intrachain disulfide bond that appeared to be crucial for QS-13 binding to cell surface. The substitution of 221 R completely abolished the adhesion. The 221 R residue might also be crucial for the binding.
QS-13 binding to αvβ3 inhibits FAK, PI3-kinase and Akt phosphorylation.
It is now well established that the FAK/PI 3 K/Akt pathway plays a critical role in the progression of melanoma. To analyse the effects of QS-13 on this transduction pathway, SK-MEL-28 melanoma cells were incubated with the QS-13 peptide for 5, 10, 20, 60 min. The expression of total proteins and their corresponding phosphorylated forms were evaluated by western blotting. The FAK Y397 /total FAK ratio was decreased by 67% at 5 min and 76% at 10 min (Fig. 6a ). The PI 3 K p85 Y458 /total PI 3 K p85 ratio decreased gradually from 33% at 5 min to 72% at 60 min (Fig. 6b ). The pAkt T308 /total Akt ratio decreased gradually from 46% after 5 min of incubation to 66% after 20 min ( Fig. 6c ). Taken together, our results demonstrated that the FAK/PI 3 K/Akt pathway is impacted by the QS-13 peptide ( Supplementary Fig. S4 ).
Discussion
Although the basement membrane provides structural support for epithelial and endothelial cells, many studies have demonstrated that it also acts as a potential regulator of cell behaviour. Type IV collagen is a major component of basement membranes and plays a pivotal role in the regulation of cell proliferation, adhesion and migration, either through its triple helical domain 21, 22 or through the NC1 domain of its constitutive α(IV) chains 4, 23 . We demonstrated that the NC1 α4(IV) domain, named Tetrastatin, exerts anti-tumor effects 19 . We synthesized shorter peptides and demonstrated that the QS-13 peptide was still able to reproduce the effect of Tetrastatin on melanoma cells in vitro and in vivo.
Tetrastatin was shown to interact with the α v β 3 integrin at the melanoma cell surface 19 . We investigated whether the QS-13 peptide was also able to interact with the α V β 3 integrin. We performed cell adhesion-blocking experiments with the QS-13 peptide and demonstrated that an α v β 3 blocking antibody inhibited cell adhesion. α v β 3 involvement in QS-13 binding to melanoma cells was confirmed by affinity chromatography. Using β 3 siRNA strategies, we confirmed the α v β 3 integrin as a receptor of the QS-13 peptide on the SK-MEL-28 cell surface.
To further investigate the interaction between QS-13 and α v β 3 , in silico experiments were conducted. The presence of a disulphide bond in the QS-13 peptide was determined by MALDI-ToF experiments. Taken together, the results of the MD simulations emphasize the role of this disulfide bond in the structure of the different investigated peptides. The presence of the disulfide bond restrains the explored configuration space, thus leading to a lower number of clusters. In addition, the constraint imposed by the presence of the disulfide bond leads to a better exposure of the side chains (glutamine and valine central residues as well as arginine and lysine residues). When considering the interaction with α v β 3 , through docking experiments, we highlighted the importance of the disulfide bond since it clearly improves the values of the free energy of binding between the QS-13 peptides and integrin.
One of the hypothetical binding areas for QS-13 deduced from the docking experiments overlaps the RGD binding site 20 . The RGD peptide inhibits SK-MEL-28 cell adhesion to QS-13. These results provide evidence that the QS-13 biding site is identical or in close proximity to the RGD binding site on α v β 3 and validate the first theoretical area suggested by the docking experiments.
Regarding the MD experiments, several amino-acids from the QS-13 peptide were suggested to be crucial for the interaction with α v β 3 . These amino-acids were sequentially replaced by an alanine residue, and modified peptides were tested for their ability to bind to the SK-MEL-28 cell surface. Substitution of the cysteines at positions 222 and 225 by alanine abolished peptide binding to SK-MEL-28. As suggested by the MD simulation and docking experiments, the disulfide bond was found to be crucial for QS-13 binding to SK-MEL-28 through α v β 3 . Although docking experiments were not performed with the mutated peptides, we can clearly draw a correlation between the results obtained with the MD simulations and observations extracted from the docking results. As stated previously, the MD simulations highlight the importance of the disulfide bond and its role in the structure and the exposure of the side chain groups. In particular, the right panel of Fig. 4a shows the accessibility of the arginine residue, which is a positively charged residue in a physiological environment and was simulated this way. Analysis of the docking indicates that there are two main contacts in term of integrin residues: the aspartate and glutamate residues, which are negatively charged amino acids. We can then postulate that arginine/aspartate or arginine/ glutamate interactions are strong favourable electrostatic interactions that contribute to a better stabilization of the position observed in the case of QS13 peptides containing the disulfide bond since it lowers the value of the binding energy of QS13 to integrin. In summary, QS-13 binding to α v β 3 appears to be conformation-dependent.
α v β 3 was reported to differentially activate cell migration and the intracellular signalling FAK/PI 3 K/AKT pathway in a ligand-specific manner 24, 25 . FAK (focal adhesion kinase) is a multifunctional protein 26 that is particularly involved in tumor invasion 27 . Phosphorylation of the PI 3 K activating subunit (p85) is important, especially because of its role in cell migration and tumor growth 28 . Reiske et al. have shown that FAK phosphorylation at Tyr-397 promotes cell migration through PI 3 K activation 29 . PI 3 K, in turn, activates Akt. Akt is a central enzyme in tumor invasion and participates in the regulation of all stages of tumor development 30 . In our experiments, FAK Y397 , PI 3 K p85 Y458 and Akt T308 phosphorylation decreased after QS-13 binding to SK-MEL-28, in agreement with the inhibition of cell migration and invasion that we observed in vitro.
Taken together, our results demonstrate that QS-13 strongly inhibits melanoma progression through α v β 3 integrin binding (Fig. 7) . This integrin is overexpressed in tumors and is a prime target for the administration of anti-cancer agents in situ 31 . The ultimate goal of this study is to propose a new therapeutic strategy based on QS-13 grafting on the surface of nanoparticles loaded with cytotoxic agents to deliver the drug specifically to the tumor, decreasing the required drug concentration side effects.
Methods
Chemicals and antibodies. Culture reagents and molecular biology products were purchased from Invitrogen (distributed by Fischer Scientific, Illkirch, France). RIPA lysis buffer, Bovine Serum Albumin, Gelatin, Matrigel and RGDS peptide were purchased from Sigma (St-Quentin, France). The anti-α v β 3 integrin antibody (23C6) was purchased from Millipore (Saint Quentin-en-Yvelines, France) and the corresponding IgG1, k control isotype (MOPC-21) was from Sigma-Aldrich. Anti-phospho-FAK (Tyr397) (dilution 1/3000), anti-FAK (dilution 1/3000), anti-phospho-PI 3 K p85 (Tyr458)/p55 (Tyr199) (dilution 1/1000) antibodies were purchased from Cell Signaling (distributed by Ozyme, Saint Quentin-en-Yvelines, France). Antiphospho-Akt (Tyr308) (dilution 1/3000) and Anti-Akt antibodies (dilution 1/3000) were purchased from Cell Signaling Technology (distributed by Ozyme, Saint Quentin en Yvelines, France). The anti-PI 3 K p85 antibody (dilution 1/2000) was purchased from Merck Millipore (Molsheim, France). The anti-actin antibody (dilution 1/10000) was purchased from Santa Cruz Biotechnology (distributed by Clinisciences, Nanterre, France). CS-50 (CHFFANKYSFWLTTVKADLQFSSAPAPDTLKESQAQRQKISRCQVCVKYS) and QS-13 (QKISRCQVCVKYS) peptides were purchased from Proteogenix (Schiltigheim, France) and used at 40 µM.
Area of Interaction (PAI) (magenta surfaces). These PAI are also evidenced through the docking experiments performed with the other peptides. The protein is represented using the New Cartoon scheme and colored according to the nature of the chain (grey for α V and brown for β 3 ) (left panel). Identification of contacts between QS-13-6 and the PAI shared with RGD peptides: contacts made with the α V subunit (central panel) and contacts made with the β3 subunit (right panel).
Scientific REPORTs | (2018) 8:9837 | DOI:10.1038/s41598-018-28003-x Cell lines. SK-MEL-28 human melanoma cells and B16-F1 murine melanoma cells were obtained from ATCC. They were cultured in DMEM and 10% FBS at 37 °C in a humid atmosphere (5% CO 2 , 95% air).
In vivo studies. All were housed in a room with a constant temperature and humidity. All mice were acclimatized to laboratory conditions for 1 week before starting the experiments. A suspension of B16F1 cells (2.5 × 10 5 cells in 0.10 mL DMEM) was subcutaneously injected into the left side of C57Bl6 mice. The tumor size was measured at days 10, 15, and 20. Mice were sacrificed at day 20 and the tumor sizes were measured. Each group contained at least 7 mice. The tumor volumes were determined according to v = ½ A × B 2 , where A denotes the largest dimension of the tumor and B represents the smallest dimension 32 .
Expression and Purification of Recombinant Human Tetrastatin. Recombinant human Tetrastatin
was prepared as described in a previous paper 19 .
In vitro proliferation assays. SK-MEL-28 proliferation was evaluated using the WST-1 reagent as described in a previous paper 19 .
Anchorage-independent growth. Soft agar assays were carried out as described in a previous paper 19 .
Scratch wound assay. SK-MEL-28 cells (5 × 10 4 per well) were seeded in 24-well plates and grown to confluence in DMEM supplemented with 10% FBS. The cell layer was then wounded with a sterile 100 to 1000 μL pipet tip and re-incubated in fresh culture medium in the absence or presence of peptide. After 72 h, cells were photographed and the size of the remaining wound was measured.
In vitro invasion assays. Invasion was assayed in modified Boyden chambers (tissue culture treated, 6.5 mm diameter, 8 μm pore, Greiner-One, Courtaboeuf, France) as described in a previous paper 19 . Figure 6 . Kinetic analysis of FAK, PI 3 K p85 and Akt phosphorylation in SK-MEL-28 cells after incubation with QS-13. Western blot analysis of phosphorylated-FAK Y397 compared to total FAK (a), phosphorylated-PI 3 K p85 Y458 compared to total PI 3 K p85 subunit (b), phosphorylated-Akt T308 compared to total Akt (c). Bands were quantified by densitometric analysis and phosphorylated proteins were reported to corresponding total proteins.
Scientific REPORTs | (2018) 8:9837 | DOI:10.1038/s41598-018-28003-x Adhesion assays. Cells were detached with 50 mM Hepes, 125 mM NaCl, 5 mM KCl and 1 mM EDTA, washed three times with DMEM and preincubated for 30 min with different effectors. 2 × 10 4 cells were seeded per well on a 96 well-plate that was previously coated with QS-13 peptide. After 60 min of adhesion, cells were washed three times with PBS, fixed with 1.1% glutaraldehyde and stained with crystal violet. After elution with 10% acetic acid, absorbance was read at 560 nm.
Flow cytometry analysis. Cells were detached with 50 mM Hepes, 125 mM NaCl, 5 mM KCl and 1 mM EDTA and washed three times with DMEM. They were incubated for 30 min with different biotinylated peptides and washed three times with DMEM. They were incubated for 30 min with Alexa Fluor 488 Streptavidin and washed three times with DMEM. They were analysed by a FACS Fortessa flow cytometer (BD Biosciences, San Jose, USA). Ten thousand cells, gated for forward scatter vs. side scatter, were collected for each sample. The results were analysed using Flow Jo software (FlowJo Enterprise, Ashland, OR, USA). Quantification of fluorescence was performed using the median fluorescence intensity (MFI).
Affinity chromatography analysis. SK-MEL-28 protein extracts were chromatographed at 4 °C on a
HiTrap NHS-activated Sepharose High Performance column (GE Healthcare ™ , Orsay, France) that was previously functionalized with the QS-13 peptide according to the manufacturer instructions. Unbound material was removed by washing with 30 mL of washing buffer (10 mM Tris, 1 mM CaCl 2 , 1 mM MgCl 2 , pH 7.6, 1 mM N-Ethylmaleimide (NEM), 1 mM phenylmethylsulfonyl fluoride (PMSF) and 0.1% octylglucoside). Proteins bound to the affinity column were then eluted with elution buffer: 10 mM Tris, pH 7.6, 1/100 PIC (ProteoBlock Protease Inhibitor Cocktail, Fermentas ™ , Illkirch, France) (w/v) and 0.1% octylglucoside supplemented with increasing concentrations of NaCl (0.15, 0.6 and 1 M). Eluted samples were then solubilized in SDS sample buffer with 10 mM DTT, denatured at 95 °C for 5 min and submitted to SDS-PAGE. Western blot analysis. Cells were incubated for 10 min with RIPA lysis buffer (1% (v/v) Triton X-100, 1%
(v/v) sodium deoxycholate, 0.1% (v/v) SDS, 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 1 mM EDTA in distilled water supplemented with the Halt ™ Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific, Illkirch, France) and scraped. Samples were mechanically resuspended by pipetting and vortexing every 5 min for 30 min. After that, they were centrifuged at 10 000 g for 10 min at 4 °C, and the resulting supernatants were quantified using a Bradford assay. Fifty micrograms of each sample was diluted in sample buffer, reduced using β-mercaptoethanol and heated at 95 °C for 10 min. Samples were analysed by western blotting as described in a previous paper 19 .
RT-qPCR. Total RNA isolation was performed using a Qiagen RNeasy kit (Qiagen, Courtaboeuf, France) according to the manufacturer's instructions. cDNA were prepared from 100 ng of total RNA by reverse transcription (RT) using a Maxima First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Villebon-sur-Yvette, France) according to the manufacturer's protocol. Real-time PCR was performed using a Maxima SYBR green/rox qPCR master mix (Thermo Fisher Scientific, Villebon-sur-Yvette, France) on the Stratagene Mx3005P qPCR detection system (Agilent technologies, Les Ulis, France). The PCR conditions were 10 min at 95 °C, followed by 40 cycles each consisting of 15 s at 95 °C (denaturation), 30 s at 60 °C (annealing) and 30 s at 72 °C (extension). After real-time PCR, melting curve analysis was performed by continuously measuring fluorescence during heating from 55 to 95 °C at a transition rate of +0.2 °C/s. Product specificity was evaluated by melting curve analysis and electrophoresis on 2% agarose gels. Fluorescence was analysed using the Data Analysis software (Stratagene). Crossing points (Cp or Ct) were established using the second derivative method. The real-time PCR efficiency was calculated from the slope of the standard curve. The target gene expression levels were normalized to the reference gene.
The following primers were used: ITGB3 forward primer: 5′-gacaagggctctggagacag-3′ and reverse primer: 5′-actggtgagctttcgcatct-3′; eEF1A1 forward primer: 5′-ctggagccaagtgctaacatgcc-3′ and reverse primer 5′-ccgggtttgagaacaccagtc-3′. siRNA transfection. Human beta 3 integrin subunit-specific siRNA and negative control siRNA (non-targeting pool) (FlexiTube GeneSolution) were purchased from Qiagen (Courtaboeuf, France). The siRNA targeted different regions of the ITGB3 mRNA: the 1st siRNA target sequence (5′-cacgtgtggcctgttcttcta-3′), 2nd siRNA target sequence (5′-caagctgaacctaatagccat-3′), 3rd siRNA target sequence (5′-ctctcctgatgtagcacttaa-3′) and 4th siRNA target sequence (5′-ccgcttcaatgaggaagtgaa-3′). Exponentially growing SK-MEL-28 cells were trans- Molecular dynamics simulations. Molecular dynamic simulations on the different peptides were conducted using the GROMACS simulation package 33, 34 . The OPLSAA force field was chosen as the set of parameters for describing the atoms and their interactions 35, 36 . Isolated peptides were placed in boxes with side lengths varying from 40 Å to 190 Å depending on their size. These values were chosen so that a given peptide would not interact with its images when the periodic boundary conditions were applied. Water (TIP3P model 37 ) and Cl − counter ions were added prior to the simulations. To relax the structures, 5000 steps of energy minimization were performed using the steepest descent algorithm. The systems were equilibrated for 500 ps at a temperature of 310 K in the isothermal-isobaric ensemble. The equilibration steps were followed by molecular dynamics (MD) simulations carried out for 200 ns, maintaining a pressure of 1 bar (Berendsen algorithm) and temperature of 310 K (V-rescale algorithm). The Verlet algorithm was used to integrate the equation from classical mechanics in parallel with an integration step of 2 fs since the length of the bonds implicating hydrogen atoms were frozen using the SHAKE algorithm 38 . For computation of the non-bonded interactions, the Particle Mesh Ewald (PME) algorithm 39, 40 was used with a cut off at 1.8 Å for the coulombic interactions and a potential-shifting function for van der Waals interactions applied at 1.3 Å and a cut off at 1.4 Å.
The trajectories of the QS-13 peptides were analysed using the clustering tool available in the GROMACS simulation package. Each of the trajectories was decomposed using the g cluster module of the GROMACS simulation package and the gromos algorithm. In order to form the different clusters or families of structures, RMSD were calculated based on the positions of the α-carbons of the peptides and a cutoff of 3 Å was set. This cutoff was chosen because it gave a good compromise between the total number of clusters obtained and also the distributions of the structures within these clusters.
Scientific REPORTs | (2018) 8:9837 | DOI:10.1038/s41598-018-28003-x Docking experiments. Docking of the QS-13 peptides against the α v β 3 integrin (RCSB Protein Data Bank 4G1M) was performed using Autodock software (version 4.2) 41 . We extracted the structure of the RGD peptide (which is known to bind to integrin α v β 3 ) from the PDB structure 1L5G and performed preliminary docking experiments to determine the relevant set of docking parameters. The software was used with a fixed integrin and semi-flexible QS13 ligand (the backbone was frozen as well as the amide links and guanadinium groups). Since the integrin is a large molecule, we performed several independent dockings targeting different subvolumes of the protein; we considered 180 overlapping boxes with a volume of 47.25 Å × 47.25 Å × 47.25 Å. Each box was divided along the three directions, and the distance between the nodes was equal to 0.375 Å. The Lamarckian genetic algorithm was used, and for each ligand, 150 dockings were performed with the default parameters of Autodock except for the population size (150), number of energy evaluations (5 × 10 6 ), and maximum number of generations (30, 000), which were derived from the preliminary study. Molecular models were graphed with VMD software, which is available online.
Quantification and statistical analyses. For in vitro experiments, results are expressed as the mean ± SD and were analysed using Student's t-test. For in vivo experiments, the volumes of the primary tumors were analysed using the non-parametric Kruskal-Wallis test.
